Focused on developing DNA-based immunotherapies and vaccines, this biotech firm targets cancers and infectious diseases. Investors monitor its clinical-stage pipeline, particularly its COVID-19 vaccine candidate that faced regulatory hurdles. The company's low market cap reflects its speculative profile as a pre-revenue biotech play.
4 members of Congress have disclosed 4 trades in Inovio Pharmaceuticals, Inc. (INO), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 2 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2020-09-08 | Christopher L. Jacobs | sell | $1K – $15K |
| 2018-06-25 | Chris Collins | buy | $15K – $50K |
| 2017-04-03 | JOHN ABNEY CULBERSON | buy | $1K – $15K |
| 2017-03-04 | Kurt Schrader | sell | $1K – $15K |